Patent · US Active

Aprepitant oral liquid formulations

US10251891B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

INNOPHARMAX, INC. · TW

Inventors

Udaya Toti · Monmouth Junction, US
Shyamprasad Mukundan · Parsippany, US
Sasank Chaitanya Kunadharaju · Edison, US
Tushar Hingorani · Bound Brook Junction, US
Kumaresh Soppimath · Colts Neck Township, US
Satish Pejaver · Bound Brook, US
Navneet Puri · Lebanon, US

Key dates

Filing date	Oct 25, 2016
Grant date	Apr 9, 2019
Priority date	—
Expiry date	Oct 25, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/146
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.